Results 31 to 40 of about 2,022,996 (246)

Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?

Frontiers in Immunology, 2017
During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells.
Thomas C. Wirth, Florian Kühnel
doaj   +1 more source

DNA Repair and Signaling in Immune-Related Cancer Therapy

Frontiers in Molecular Biosciences, 2020
Cancer therapy using immune checkpoint inhibitors (ICIs) is a promising clinical strategy for patients with multiple types of cancer. The expression of programmed cell death ligand-1 (PD-L1), an immune-suppressor ligand, in cancer cells is a factor that ...
Sangeeta Kakoti, Sangeeta Kakoti, Hiro Sato, Siddhartha Laskar, Takaaki Yasuhara, Takaaki Yasuhara, Atsushi Shibata   +6 more
doaj   +1 more source

Site-specific neoepitope induction by RNA editing reprograms tumor immunogenicity

Frontiers in Immunology
IntroductionNeoantigens derived from somatic mutations exhibit high immunogenicity and specificity. However, their stochastic nature necessitates personalized vaccine design, and cancers with low tumor mutational burden often have insufficient neoantigen
Shangyuan Liu, Chunxiu Dong, Lin Chen, Jiahong Yan, Xiaoshan Luo, HaiChao Huang, Zonghao Qiu, Xuhong Gan, Jiali Yang, Jiafeng Zhu, Chengjie Xiong, Lihong Huang, Linlin Wang, Zhengning Yang, Zhongxuan Meng, Senrong Yi, Yuxin Chen, Chijian Zuo, Qibin Leng, Xiaoling Wang   +19 more
doaj   +1 more source

Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis

Frontiers in Immunology, 2023
IntroductionIdentification of tumor specific neoantigen (TSN) immunogenicity is crucial to develop peptide/mRNA based anti-tumoral vaccines and/or adoptive T-cell immunotherapies; thus, accurate in-silico classification/prioritization proves critical for
Guadalupe Nibeyro, Veronica Baronetto, Juan I. Folco, Pablo Pastore, Maria Romina Girotti, Laura Prato, Gabriel Morón, Gabriel Morón, Hugo D. Luján, Hugo D. Luján, Elmer A. Fernández, Elmer A. Fernández, Elmer A. Fernández   +12 more
doaj   +1 more source

Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419

Frontiers in Oncology, 2022
BackgroundTriple negative breast cancer (TNBC) is an aggressive variant of breast cancer that lacks the expression of estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients with advanced TNBC will develop brain metastases (BrM),
Eric D. Routh, Amanda E. D. Van Swearingen, Maria J. Sambade, Steven Vensko, Marni B. McClure, Marni B. McClure, Mark G. Woodcock, Mark G. Woodcock, Shengjie Chai, Shengjie Chai, Luz A. Cuaboy, Amy Wheless, Amy Garrett, Lisa A. Carey, Lisa A. Carey, Alan P. Hoyle, Joel S. Parker, Joel S. Parker, Benjamin G. Vincent, Benjamin G. Vincent, Benjamin G. Vincent, Benjamin G. Vincent, Benjamin G. Vincent, Carey K. Anders, Carey K. Anders   +24 more
doaj   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

Unique circulating miRNAome signatures captured with distinct molecular states in Lynch syndrome and sporadic colorectal cancer

Molecular Oncology, EarlyView.
Circulating microRNA profiles distinguish nonmalignant Lynch syndrome from cancer‐associated Lynch syndrome, sporadic colorectal cancer, and healthy controls. Age‐stratified analysis reveals disease‐specific regulatory states, and a six‐miRNA panel shows concordant separation in an independent colorectal tissue cohort.
Ramadhani Salum Chambuso, Md Shohel Ul Islam, Rosa M Xicola, Raj Ramesar, Xavier Llor, Sinclair Steele   +5 more
wiley   +1 more source

Challenges in neoantigen-directed therapeutics

, 2023
: A fundamental prerequisite for the efficacy of cancer immunotherapy is the presence of functional, antigen -specific T cells within the tumor. Neoantigen-directed therapy is a promising strategy that aims at targeting the host's immune response against
Fant, Bruno, Feldman, Steven A., Dirix, Luc, De Geest, Bruno, Lybaert, Lien, Van Criekinge, Wim, Lefever, Steve, Thielemans, Kris, Breckpot, Karine, Smits, Evelien, van der Burg, Sjoerd H., Ott, Patrick A., Bogaert, Cedric, Kris Thielemans, Lien Lybaert, Luc Dirix, Bruno De Geest, Cedric Bogaert, Wim van Criekinge, Steve Lefever, Steven A. Feldman, Karine Breckpot, Patrick A. Ott, Bruno Fant, Evelien Smits, Sjoerd H. van der Burg   +25 more
core   +2 more sources

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity

Frontiers in Immunology, 2019
Tumor vaccines are an important asset in the field of cancer immunotherapy. Whether prophylactic or therapeutic, these vaccines aim to enhance the T cell-mediated anti-tumor immune response that is orchestrated by dendritic cells.
Felix L. Fennemann, I. Jolanda M. de Vries, I. Jolanda M. de Vries, Carl G. Figdor, Carl G. Figdor, Carl G. Figdor, Martijn Verdoes, Martijn Verdoes   +7 more
doaj   +1 more source